15001 Durable efficacy of certolizumab pegol dosed at 400 mg every two weeks over 128 weeks in patients with plaque psoriasis enrolled in three phase 3 trials (CIMPASI-1, CIMPASI-2, and CIMPACT)

Authors :: Diamant Thaçi
Richard B. Warren
Marion Boehnlein
Kristian Reich
C Arendt
Andrew Blauvelt
Fiona Brock
Yves Poulin
Alice B. Gottlieb
Kenneth B. Gordon
Source :: Journal of the American Academy of Dermatology. 83:AB139
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Plaque psoriasis
medicine.medical_specialty
Every Two Weeks
business.industry
Internal medicine
medicine
In patient
Dermatology
Certolizumab pegol
business
Gastroenterology
medicine.drug

Full Text Access

Tools